clinical trial · NCT07459543
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb·phase4·not yet recruiting·n = 30
Untreated MelanomaUnresectable MelanomaMetastatic MelanomaNivolumab + Relatlimab
brief summary
The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in untreated, unresectable or metastatic melanoma participants in India
started
Nov 15, 2026
primary completion
May 26, 2029
completion
May 28, 2029
last updated
Mar 9, 2026
official title
A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Previously Untreated, Unresectable or Metastatic Melanoma in India.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol